Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mircera Dosage at Altitude in Chronic Renal Anemia
NCT01519947Phase 4Completed
- Sponsor
- Roche
- Start
- May 2012
- Primary completion
- May 2015
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, open-label trial of methoxy polyethylene glycol-epoetin beta in anemia of chronic kidney disease (CKD-A) (4 arms), sponsored by Roche. Primary endpoint: Mean Dose Required to Achieve Target Hemoglobin of 11-12 g/dL at 20 months. Started May 2012; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT01519947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01519947.